Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment

Cancer Science

Volumn 105, Issue 8, 2014, Pages 966-973

  Tanizaki, Yuko ^a   Kobayashi, Aya ^a   Toujima, Saori ^a   Shiro, Michihisa ^a   Mizoguchi, Mika ^a   Mabuchi, Yasushi ^a   Yagi, Shigetaka ^a   Minami, Sawako ^a   Takikawa, Osamu ^b   Ino, Kazuhiko ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Immunosuppression; Indoleamine 2,3 dioxygenase; Ovarian cancer; Peritoneal dissemination; Tolerance

Indexed keywords

1 METHYLTRYPTOPHAN; COMPLEMENTARY DNA; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG TARGETING; FEMALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

IMMUNOSUPPRESSION; INDOLEAMINE 2,3-DIOXYGENASE; OVARIAN CANCER; PERITONEAL DISSEMINATION; TOLERANCE;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84906794260     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12445     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
3. Gajewski TF, Meng Y, Blank C et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006; 213: 131-45.
4. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-27.
5. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74.
6. Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010; 117: 366-72.
7. Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 2011; 30: 141-51.
8. Abiko K, Mandai M, Hamanishi J et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 2013; 19: 1363-74.
9. Takikawa O. Biochemical and medical aspects of the indoleamine 2, 3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun 2005; 338: 12-9.
10. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-3.
11. Munn DH, Sharma MD, Hou D et al. Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114: 280-90.
12. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002; 196: 459-68.
13. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2, 3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008; 181: 5396-404.
14. Wainwright DA, Balyasnikova IV, Chang AL et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 2012; 18: 6110-21.
15. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 2003; 9: 1269-74.
16. Okamoto A, Nikaido T, Ochiai K et al. Indoleamine 2, 3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005; 11: 6030-9.
17. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011; 17: 6985-91.
18. Ino K, Yoshida N, Kajiyama H et al. Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006; 95: 1555-61.
19. Ino K, Yamamoto E, Shibata K et al. Inverse correlation between tumoral indoleamine 2, 3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 2008; 14: 2310-7.
20. Inaba T, Ino K, Kajiyama H et al. Role of the immunosuppressive enzyme indoleamine 2, 3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 2009; 115: 185-92.
21. Yoshida N, Ino K, Ishida Y et al. Overexpression of indoleamine 2, 3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 2008; 14: 7251-9.
22. Habara-Ohkubo A, Takikawa O, Yoshida R. Cloning and expression of a cDNA encoding mouse indoleamine 2, 3-dioxygenase. Gene 1991; 105: 221-7.
23. Toyoshima M, Tanaka Y, Matumoto M et al. Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging. Luminescence 2009; 24: 324-31.
24. Yamamura S, Matsumura N, Mandai M et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer 2012; 130: 20-8.
25. Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2, 3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 1988; 263: 2041-8.
26. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994; 73: 1882-8.
27. Mustea A, Konsgen D, Braicu EI et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 2006; 26: 1715-8.
28. Chen YL, Chang MC, Chen CA, Lin HW, Cheng WF, Chien CL. Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses. PLoS ONE 2012; 7: e47190.
29. Liu CZ, Zhang L, Chang XH et al. Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chin J Cancer Res 2012; 24: 130-7.
30. Nonaka H, Saga Y, Fujiwara H et al. Indoleamine 2, 3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killer cell function and angiogenesis promotion. Int J Oncol 2011; 38: 113-20.
31. Wang D, Saga Y, Mizukami H et al. Indoleamine-2, 3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol 2012; 40: 929-34.
32. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
33. Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res 2010; 316: 2713-22.
34. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013; 210: 1389-402.
35. Smith C, Chang MY, Parker KH et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2012; 2: 722-35.
36. 1-Methyl-D-Tryptophan in treating patients with metastatic or refractory solid tumors that cannot be removed by surgery. Information provided by National Cancer Institute (NCI). http://clinicaltrials.gov/ct2/show/study/NCT00567931.